DrugPatentWatch Database Preview

FABIOR Drug Profile

« Back to Dashboard

Which patents cover Fabior, and what generic alternatives are available?

Fabior is a drug marketed by Mayne Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-three patent family members in seventeen countries.

The generic ingredient in FABIOR is tazarotene. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the tazarotene profile page.

Summary for FABIOR

International Patents:	23
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	97
Clinical Trials:	1
Patent Applications:	4,398
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for FABIOR
DailyMed Link:	FABIOR at DailyMed

See drug prices for FABIOR

Recent Clinical Trials for FABIOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Actavis Inc.	Phase 3

See all FABIOR clinical trials

Pharmacology for FABIOR

Drug Class

Retinoid

Synonyms for FABIOR

118292-40-3

15146-EP2275420A1

15146-EP2295055A2

15146-EP2295416A2

15146-EP2298748A2

15146-EP2298764A1

15146-EP2298765A1

15146-EP2298768A1

15146-EP2305642A2

15146-EP2308861A1

15146-EP2311453A1

15146-EP2311808A1

15146-EP2311829A1

15146-EP2314590A1

15146-EP2316832A1

15146-EP2316833A1

292T403

3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester

3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-,ethyl ester

4CA-1215

6-(4,4-Dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester

6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid ethyl ester

6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester

6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-pyridinecarboxylic Acid Ethyl Ester

6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester

6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylicacidethylester

81BDR9Y8PS

AB0012671

AB01274801_02

AB01274801-01

AB2000146

ABP000994

AC-755

AC1L1K88

Acnitaz

ACT06773

AGN 190168

AGN-190168

AGN190168, AGN-190168

AJ-26850

AKOS015902872

AN-15540

ANW-45265

Avage

Avage (TN)

AX8041205

BC201578

BCP0726000163

BCP22966

BDBM50265951

BIDD:GT0293

BR-73028

BS-1012

C-23771

C12531

C21H21NO2S

CAS-118292-40-3

CC-34651

CHEBI:32184

CHEMBL1657

CJ-24315

CS-1029

CTK8B4490

D01132

DB00799

DSSTox_CID_26691

DSSTox_GSID_46691

DSSTox_RID_81825

DTXSID5046691

EBD38650

Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate

Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate;6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid ethyl ester

ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)-ethynyl)nicotinate

ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate

ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate

Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate

ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate

ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate

Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate

ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate

Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate

ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]pyridine-3-carboxylate

Fabior (TN)

FT-0652578

GTPL6952

HMS3655K05

HY-15388

I14-1992

KB-80817

LS-130838

MLS003915630

MolPort-005-932-693

NCGC00167525-01

NCGC00167525-02

NCGC00167525-03

OGQICQVSFDPSEI-UHFFFAOYSA-N

PubChem24431

Q-102516

RTR-034197

S-7551

s1569

SC-19506

SCHEMBL3134

SMR002096194

SR-01000931253

SR-01000931253-2

ST2419369

Suretin

SW220026-1

tazarotene

Tazarotene (Avage)

Tazarotene (JAN/USAN/INN)

Tazarotene [USAN:INN:BAN]

Tazarotene [USAN:INN]

Tazarotene,(S)

tazaroteno

tazarotenum

Tazorac

Tazorac (TN)

Tazorac;Avage;Zora;Avage

Tazoral

Tox21 112522

Tox21_112522

Tox21_112522_1

TR-034197

UNII-81BDR9Y8PS

ZINC1542199

Zora

Zorac

Zorac|||Tazorac

US Patents and Regulatory Information for FABIOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	FABIOR	tazarotene	AEROSOL, FOAM;TOPICAL	202428-001	May 11, 2012		RX	Yes	Yes			Y

International Patents for FABIOR

Country	Patent Number	Estimated Expiration
China	102438590
Japan	2012518662
South Korea	101725196
Australia	2010217190
Eurasian Patent Organization	020844

Supplementary Protection Certificates for FABIOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0031058	98C0008	Belgium		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
0284288	12/1998	Austria		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
0284288	SPC/GB98/002	United Kingdom		PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730